SEC Tracker
Get the app

Whitehawk Therapeutics WHWK

Whitehawk Therapeutics reported a $21.21 million net loss for the three months ended Sep 30, 2026.

Whitehawk Therapeutics (WHWK) filed a 10-Q with the SEC on Nov 9, 2026, 4:07 pm ET. Source: the filing on SEC EDGAR.

Form
10-Q
Filed
Importance
Notable
  1. Revenue was $0 for the three months ended Sep 30, 2026.
  2. Diluted EPS was -$0.23 for the three months ended Sep 30, 2026.
  3. Cash and equivalents were $68.97 million as of Sep 30, 2026.

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Whitehawk Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.